Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues

Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues

HER2 overexpression and anti-HER2 agents represent probably the best story of success of individualized therapy in breast cancer. Due to the important therapeutic implications, the issue under the spotlight has been, since ever, the correct identification of true HER2 positivity on tissue specimens....

Full description

Bibliographic Details
Main Authors:	Anna eSapino, Margherita eGoia, Daniele eRecupero, Caterina eMarchio
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-05-01
Series:	Frontiers in Oncology
Subjects:	therapy diagnosis test HER2 truncated HER2 CEP17 amplification
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00129/full

Similar Items

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
by: Soomin Ahn, et al.
Published: (2020-01-01)

HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
by: Marina Popović, et al.
Published: (2023-05-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Targeting HER2 expression in cancer: New drugs and new indications
by: Semir Vranić, et al.
Published: (2021-02-01)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
by: Xiuwen Guan, et al.
Published: (2020-02-01)

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
by: Enrico Berrino, et al.
Published: (2022-08-01)

<i>HER2</i> Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
by: Burak Gonullu, et al.
Published: (2023-02-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
by: Fnu Amisha, et al.
Published: (2023-05-01)

Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
by: Miladinović Mirjana, et al.
Published: (2021-10-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
by: Ziteng Li, et al.
Published: (2020-12-01)

Analysis of HER2 gene amplification using Differential PCR in breast cancer patients of Isfahan Province
by: Zohreh Hojati, et al.
Published: (2014-10-01)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
by: Guangjian Yang, et al.
Published: (2022-08-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
by: Michelle D. Hackshaw, et al.
Published: (2021-08-01)

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
by: Elham Sajjadi, et al.
Published: (2023-04-01)

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
by: Katrin Almstedt, et al.
Published: (2023-02-01)

Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges
by: Marie Brevet, et al.
Published: (2024-12-01)

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
by: Insu Jeon, et al.
Published: (2020-07-01)

Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy
by: S kargar, et al.
Published: (2013-10-01)

Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii
by: Georgiy Avraamovich Frank, et al.
Published: (2013-09-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
by: Lisandra Negrón-Vega, et al.
Published: (2022-09-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Ekspresi HER2/neu(c-ErbB2) pada Kanker Kolorektal
by: Nita Afriani, et al.
Published: (2014-12-01)

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
by: Natalie F. Uy, et al.
Published: (2022-08-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
by: Emilia Rabia, et al.
Published: (2021-01-01)

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
by: Santiago Terán, et al.
Published: (2023-10-01)

Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
by: Huina Zhang, et al.
Published: (2022-12-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke
by: Erika Matos
Published: (2008-06-01)